Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2102 in HER2-Expressing Relapsed/Metastatic Breast Cancer
NCT06115902Phase 1Completed
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Nov 2023
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB2102 in breast cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoint: Overall Response Rate at 10 months. Started Nov 2023; status: completed.
02
Drugs
TQB2102
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06115902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06115902.